Microablative Fractional CO2 Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer: A Pilot Study at 4-week Follow-up

Stefano Salvatore, Rossella E. Nappi, Arianna Casiraghi, Alessandro F. Ruffolo, Rebecca Degliuomini, Marta Parma, Umberto Roberti Leone Maggiori, Stavros Athanasiou, Massimo Candiani

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this pilot study is to assess the efficacy and safety of microablative fractional CO2 laser for treating vulvovaginal (VVA) symptoms in women with a history of breast cancer (BC) at 20-week follow-up since the first laser treatment. We enrolled 40 women with a history of BC and who currently were or had been on treatment with endocrine therapy for their condition. Each of them was treated with 5 laser applications (one every 4 weeks), and the effects of the laser treatment on VVA symptoms were measured using a 10-cm visual analog scale after 20 weeks of follow-up. Changes in the Vaginal Health Index after treatment were compared with baseline. Changes in overall quality of life were assessed with a generic quality of life questionnaire: Short Form 12. Sexual function was evaluated by the Female Sexual Function Index. After 20 weeks of follow-up, microablative fractional CO2 laser was safe and effective in treating VVA symptoms in women with a history of BC, irrespective of being previously or currently on endocrine therapies.

Original languageEnglish
JournalClinical Breast Cancer
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • Dyspareunia
  • Menopause
  • Sexual function
  • Sexual intercourse
  • Vaginal dryness

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Microablative Fractional CO<sub>2</sub> Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer: A Pilot Study at 4-week Follow-up'. Together they form a unique fingerprint.

Cite this